In this present proof of principle investigation, we have shown that agonistic OX40 antibody in combination with HT and RT as tripartite treatment significantly inhibited PC-tumor growth until 45 days in a preclinical study. The gene discussed is TNFRSF4; the disease is pachyonychia congenita.